We have had a gutful

The need for deprescribing proton pump inhibitors

M. Naunton, G. M. Peterson, L. S. Deeks, H. Young, S. Kosari

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

What is known and objective: Proton pump inhibitor (PPI) prescribing may often be inappropriate and expose patients to a risk of adverse effects, while incurring unnecessary healthcare expenditure. Our objective was to determine PPI usage in Australia since 2002 and review international studies investigating inappropriate PPI prescribing, including those that discussed interventions to address this issue. Methods: Australian Pharmaceutical Benefits Scheme (PBS) and Repatriation Pharmaceutical Benefits Scheme (RPBS) data were analysed. A narrative literature review relevant to the objective was conducted. Time series analysis was also used to examine the trend of reported PPI appropriate use across the international studies included in this review. Results and discussion: Proton pump inhibitor use in Australia increased between 2002 and 2010 and then gradually decreased. Estimates of the extent of inappropriate use in the international literature had a wide variation (11-84%). There appeared to be little change in the extent of appropriate PPI use reported through 34 international studies from 2000 to 2016. Interventions to address inappropriate use included patient-centred deprescribing, academic detailing, educational programmes and drug safety notifications. What is new and Conclusion: Proton pump inhibitors continue to be overused worldwide and should be a focus for deprescribing programmes. Ongoing education and awareness campaigns for health professionals and patients, including electronic reminders at the point of prescribing, are strategies that have potential to reduce PPI use in individuals who do not have an evidence-based clinical indication for their long-term use.

Original languageEnglish
Pages (from-to)65-72
Number of pages8
JournalJournal of Clinical Pharmacy and Therapeutics
Volume43
Issue number1
DOIs
Publication statusPublished - 1 Feb 2018

Fingerprint

Proton Pump Inhibitors
Pharmaceutical Preparations
Deprescriptions
Health Expenditures
Health Promotion
Delivery of Health Care
Safety
Education

Cite this

@article{a8d1822af2e3466986df89d98891fdc6,
title = "We have had a gutful: The need for deprescribing proton pump inhibitors",
abstract = "What is known and objective: Proton pump inhibitor (PPI) prescribing may often be inappropriate and expose patients to a risk of adverse effects, while incurring unnecessary healthcare expenditure. Our objective was to determine PPI usage in Australia since 2002 and review international studies investigating inappropriate PPI prescribing, including those that discussed interventions to address this issue. Methods: Australian Pharmaceutical Benefits Scheme (PBS) and Repatriation Pharmaceutical Benefits Scheme (RPBS) data were analysed. A narrative literature review relevant to the objective was conducted. Time series analysis was also used to examine the trend of reported PPI appropriate use across the international studies included in this review. Results and discussion: Proton pump inhibitor use in Australia increased between 2002 and 2010 and then gradually decreased. Estimates of the extent of inappropriate use in the international literature had a wide variation (11-84{\%}). There appeared to be little change in the extent of appropriate PPI use reported through 34 international studies from 2000 to 2016. Interventions to address inappropriate use included patient-centred deprescribing, academic detailing, educational programmes and drug safety notifications. What is new and Conclusion: Proton pump inhibitors continue to be overused worldwide and should be a focus for deprescribing programmes. Ongoing education and awareness campaigns for health professionals and patients, including electronic reminders at the point of prescribing, are strategies that have potential to reduce PPI use in individuals who do not have an evidence-based clinical indication for their long-term use.",
keywords = "deprescribing, gastro-oesophageal reflux, PPI, prescribing patterns, proton pump inhibitor",
author = "M. Naunton and Peterson, {G. M.} and Deeks, {L. S.} and H. Young and S. Kosari",
note = "{\circledC} 2017 John Wiley & Sons Ltd.",
year = "2018",
month = "2",
day = "1",
doi = "10.1111/jcpt.12613",
language = "English",
volume = "43",
pages = "65--72",
journal = "Journal of Clinical and Hospital Pharmacy",
issn = "0269-4727",
publisher = "Wiley-Blackwell",
number = "1",

}

We have had a gutful : The need for deprescribing proton pump inhibitors. / Naunton, M.; Peterson, G. M.; Deeks, L. S.; Young, H.; Kosari, S.

In: Journal of Clinical Pharmacy and Therapeutics, Vol. 43, No. 1, 01.02.2018, p. 65-72.

Research output: Contribution to journalArticle

TY - JOUR

T1 - We have had a gutful

T2 - The need for deprescribing proton pump inhibitors

AU - Naunton, M.

AU - Peterson, G. M.

AU - Deeks, L. S.

AU - Young, H.

AU - Kosari, S.

N1 - © 2017 John Wiley & Sons Ltd.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - What is known and objective: Proton pump inhibitor (PPI) prescribing may often be inappropriate and expose patients to a risk of adverse effects, while incurring unnecessary healthcare expenditure. Our objective was to determine PPI usage in Australia since 2002 and review international studies investigating inappropriate PPI prescribing, including those that discussed interventions to address this issue. Methods: Australian Pharmaceutical Benefits Scheme (PBS) and Repatriation Pharmaceutical Benefits Scheme (RPBS) data were analysed. A narrative literature review relevant to the objective was conducted. Time series analysis was also used to examine the trend of reported PPI appropriate use across the international studies included in this review. Results and discussion: Proton pump inhibitor use in Australia increased between 2002 and 2010 and then gradually decreased. Estimates of the extent of inappropriate use in the international literature had a wide variation (11-84%). There appeared to be little change in the extent of appropriate PPI use reported through 34 international studies from 2000 to 2016. Interventions to address inappropriate use included patient-centred deprescribing, academic detailing, educational programmes and drug safety notifications. What is new and Conclusion: Proton pump inhibitors continue to be overused worldwide and should be a focus for deprescribing programmes. Ongoing education and awareness campaigns for health professionals and patients, including electronic reminders at the point of prescribing, are strategies that have potential to reduce PPI use in individuals who do not have an evidence-based clinical indication for their long-term use.

AB - What is known and objective: Proton pump inhibitor (PPI) prescribing may often be inappropriate and expose patients to a risk of adverse effects, while incurring unnecessary healthcare expenditure. Our objective was to determine PPI usage in Australia since 2002 and review international studies investigating inappropriate PPI prescribing, including those that discussed interventions to address this issue. Methods: Australian Pharmaceutical Benefits Scheme (PBS) and Repatriation Pharmaceutical Benefits Scheme (RPBS) data were analysed. A narrative literature review relevant to the objective was conducted. Time series analysis was also used to examine the trend of reported PPI appropriate use across the international studies included in this review. Results and discussion: Proton pump inhibitor use in Australia increased between 2002 and 2010 and then gradually decreased. Estimates of the extent of inappropriate use in the international literature had a wide variation (11-84%). There appeared to be little change in the extent of appropriate PPI use reported through 34 international studies from 2000 to 2016. Interventions to address inappropriate use included patient-centred deprescribing, academic detailing, educational programmes and drug safety notifications. What is new and Conclusion: Proton pump inhibitors continue to be overused worldwide and should be a focus for deprescribing programmes. Ongoing education and awareness campaigns for health professionals and patients, including electronic reminders at the point of prescribing, are strategies that have potential to reduce PPI use in individuals who do not have an evidence-based clinical indication for their long-term use.

KW - deprescribing

KW - gastro-oesophageal reflux

KW - PPI

KW - prescribing patterns

KW - proton pump inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85040017792&partnerID=8YFLogxK

U2 - 10.1111/jcpt.12613

DO - 10.1111/jcpt.12613

M3 - Article

VL - 43

SP - 65

EP - 72

JO - Journal of Clinical and Hospital Pharmacy

JF - Journal of Clinical and Hospital Pharmacy

SN - 0269-4727

IS - 1

ER -